MedPath

Digoxin

Generic Name
Digoxin
Brand Names
Digox, Lanoxin
Drug Type
Small Molecule
Chemical Formula
C41H64O14
CAS Number
20830-75-5
Unique Ingredient Identifier
73K4184T59
Background

Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

This drug originates from the foxglove plant, also known as the Digitalis plant, studied by William Withering, an English physician and botanist in the 1780s. Prior to this, a Welsh family, historically referred to as the Physicians of Myddvai, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.

Indication

Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.

In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.

Associated Conditions
Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

A Study of MK-1084 With Midazolam and Digoxin in Healthy Participants (MK-1084-009)

Phase 1
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2024-08-28
Last Posted Date
2024-11-08
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
28
Registration Number
NCT06575933
Locations
🇺🇸

Celerion ( Site 0001), Tempe, Arizona, United States

Bioequivalence Study of Digoxin Tablet in Healthy Subjects

Phase 1
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2024-08-09
Last Posted Date
2024-08-09
Lead Sponsor
Xiangya Hospital of Central South University
Target Recruit Count
80
Registration Number
NCT06546215
Locations
🇨🇳

Xiangya Hospital Central South University, Changsha, Hunan, China

A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: LY4100511 (DC-853) Dose 1
Drug: LY4100511 (DC-853) Dose 2
Drug: LY4100511 (DC-853) Dose 3
First Posted Date
2024-07-16
Last Posted Date
2025-01-24
Lead Sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Target Recruit Count
49
Registration Number
NCT06503679
Locations
🇺🇸

Fortrea Clinical Research Unit, Dallas, Texas, United States

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2024-05-16
Last Posted Date
2025-02-06
Lead Sponsor
Incyte Corporation
Target Recruit Count
71
Registration Number
NCT06416800
Locations
🇺🇸

Fortrea Clinical Research Unit, Dallas, Texas, United States

Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects

First Posted Date
2024-04-04
Last Posted Date
2024-04-04
Lead Sponsor
Jemincare
Target Recruit Count
72
Registration Number
NCT06348290

A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2024-03-28
Last Posted Date
2025-05-08
Lead Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Target Recruit Count
57
Registration Number
NCT06335134
Locations
🇨🇳

West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
First Posted Date
2024-03-05
Last Posted Date
2024-07-22
Lead Sponsor
Eccogene
Target Recruit Count
48
Registration Number
NCT06293742
Locations
🇺🇸

Eccogene Investigational Site, Anaheim, California, United States

Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects

First Posted Date
2024-02-08
Last Posted Date
2024-08-21
Lead Sponsor
Beijing Dongfang Biotech Co., Ltd.
Target Recruit Count
28
Registration Number
NCT06247748
Locations
🇨🇳

Peking University Third Hospital drug clinical trial Institute, Beijing, Beijing, China

Digoxin and Senolysis in Heart Failure and Diabetes Mellitus

Phase 2
Not yet recruiting
Conditions
Diabetes Mellitus, Type 2
Heart Failure, Systolic
Interventions
First Posted Date
2024-02-05
Last Posted Date
2024-12-06
Lead Sponsor
University of Leeds
Target Recruit Count
100
Registration Number
NCT06240403
Locations
🇬🇧

Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-01-08
Last Posted Date
2025-02-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
16
Registration Number
NCT06194214
Locations
🇺🇸

Covance Clinical Research Unit, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath